119 related articles for article (PubMed ID: 35349735)
1. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
Lee SH; Yim SY; Jeong YS; Li QX; Kang SH; Sohn BH; Kumar SV; Shin JH; Choi YR; Shim JJ; Kim H; Kim JH; Kim S; Guo S; Johnson RL; Kaseb A; Kang KJ; Chun YS; Jang HJ; Lee BG; Woo HG; Ha MJ; Akbani R; Roberts LR; Wheeler DA; Lee JS
Hepatology; 2022 Dec; 76(6):1634-1648. PubMed ID: 35349735
[TBL] [Abstract][Full Text] [Related]
2. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
3. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
4. Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas.
Evason KJ; Grenert JP; Ferrell LD; Kakar S
Hum Pathol; 2013 May; 44(5):750-8. PubMed ID: 23084586
[TBL] [Abstract][Full Text] [Related]
5. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection.
Désert R; Rohart F; Canal F; Sicard M; Desille M; Renaud S; Turlin B; Bellaud P; Perret C; Clément B; Lê Cao KA; Musso O
Hepatology; 2017 Nov; 66(5):1502-1518. PubMed ID: 28498607
[TBL] [Abstract][Full Text] [Related]
6. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence.
Zulehner G; Mikula M; Schneller D; van Zijl F; Huber H; Sieghart W; Grasl-Kraupp B; Waldhör T; Peck-Radosavljevic M; Beug H; Mikulits W
Am J Pathol; 2010 Jan; 176(1):472-81. PubMed ID: 20008139
[TBL] [Abstract][Full Text] [Related]
7. Clinically conserved genomic subtypes of gastric adenocarcinoma.
Jeong YS; Eun YG; Lee SH; Kang SH; Yim SY; Kim EH; Noh JK; Sohn BH; Woo SR; Kong M; Nam DH; Jang HJ; Lee HS; Song S; Oh SC; Lee J; Ajani JA; Lee JS
Mol Cancer; 2023 Sep; 22(1):147. PubMed ID: 37674200
[TBL] [Abstract][Full Text] [Related]
8. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
9. Low
Yim SY; Kang SH; Shin JH; Jeong YS; Sohn BH; Um SH; Lee JS
Cells; 2020 Sep; 9(9):. PubMed ID: 32878261
[TBL] [Abstract][Full Text] [Related]
10. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
11. Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer.
Yim SY; Shim JJ; Shin JH; Jeong YS; Kang SH; Kim SB; Eun YG; Lee DJ; Conner EA; Factor VM; Moore DD; Johnson RL; Thorgeirsson SS; Lee JS
Mol Cancer Res; 2018 Nov; 16(11):1713-1723. PubMed ID: 30082483
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
Huang X; Yang C; Wang J; Sun T; Xiong H
Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
[TBL] [Abstract][Full Text] [Related]
13. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
14. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
15. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma.
Tsai MC; Huang CC; Wei YC; Liu TT; Lin MT; Yi LN; Lin PR; Wang CC; Chu TH; Hsiao CC; Hu TH; Tai MH
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192213
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
Hu B; Li H; Guo W; Sun YF; Zhang X; Tang WG; Yang LX; Xu Y; Tang XY; Ding GH; Qiu SJ; Zhou J; Li YX; Fan J; Yang XR
Int J Cancer; 2020 Mar; 146(6):1606-1617. PubMed ID: 31310010
[TBL] [Abstract][Full Text] [Related]
17. [TRIM21 suppresses invasion of hepatocellular carcinoma cells by promoting β-catenin ubiquitylation and degradation].
Zhang Z; Zhu Z; Sheng H; Sun J; Cao C
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jan; 42(1):55-62. PubMed ID: 35249870
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
Ladeiro Y; Couchy G; Balabaud C; Bioulac-Sage P; Pelletier L; Rebouissou S; Zucman-Rossi J
Hepatology; 2008 Jun; 47(6):1955-63. PubMed ID: 18433021
[TBL] [Abstract][Full Text] [Related]
19. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
[TBL] [Abstract][Full Text] [Related]
20. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
